A brand new meta-analysis combining 22 research, to be introduced on the Annual Assembly of the European Affiliation for the Examine of Diabetes (EASD) in Hamburg, Germany (2–6 October), reveals that tirzepatide is superior to semaglutide for each management of blood sugar and when it comes to quantity of physique weight misplaced by sufferers. The examine is by Dr. Thomas Karagiannis, Aristotle College of Thessaloniki, Thessaloniki, Greece, and colleagues.
Semaglutide is accredited for remedy of kind 2 diabetes and in addition weight problems/weight reduction administration. Tirzepatide has been accredited for treating kind 2 diabetes and its producers have submitted functions for its approval for weight problems/weight reduction administration.
There are few randomized managed trials (RCTs) straight evaluating subcutaneous tirzepatide with subcutaneous semaglutide. On this new analysis, the authors mixed the information from 22 out there trials to carry out a meta-analysis to match tirzepatide with semaglutide when it comes to their efficacy and security in folks with kind 2 diabetes.
The authors searched Medline and the Cochrane Library for RCTs that assessed a upkeep dose of subcutaneous tirzepatide 5, 10, or 15 mg once-weekly or subcutaneous semaglutide 0.5, 1.0, or 2.0 mg once-weekly for at the very least 12 weeks.
Comparators have been any of the eligible doses of tirzepatide and semaglutide, placebo, and in addition different glucose-lowering medication offered they have been straight in comparison with tirzepatide and semaglutide in at the very least one trial. The meta-analysis then calculated any variations in results on HbA1c (glycated hemoglobin, a measure of blood sugar management), physique weight, and in addition the danger of adversarial occasions.
The 22 RCTs included information from 18,472 sufferers, all with a prognosis of kind 2 diabetes. The authors discovered that tirzepatide 15 mg was essentially the most efficacious in decreasing HbA1c versus placebo (imply distinction -2.00%), adopted by tirzepatide 10 mg (-1.86%) and semaglutide 2.0 mg (-1.62%).
Every of the three tirzepatide doses decreased HbA1c greater than the respective low-, medium-, and high-dose of semaglutide. Versus placebo, tirzepatide was extra efficacious in decreasing physique weight (-10.96 Kg, -8.75 Kg, and -6.16 Kg for tirzepatide 15, 10, and 5 mg respectively) than semaglutide (-5.24 Kg, -4.44 Kg, and -2.72 Kg for semaglutide 2.0, 1.0, and 0.5 mg respectively).
Relating to between-drug comparisons, each tirzepatide 10 and 15 mg have been extra efficacious in decreasing physique weight versus semaglutide 0.5, 1.0, and a pair of.0 mg, whereas tirzepatide 5 mg was extra efficacious versus semaglutide 0.5 and 1.0 mg.
Though not within the journal summary, the authors have been in a position to present outcomes for change in physique weight from the analyses evaluating tirzepatide and semaglutide (slightly than versus placebo). These numerical values can be introduced within the oral presentation within the congress.
The precise variations in change in physique weight (imply distinction) for the next comparisons are:
- Tirzepatide 15 mg versus semaglutide 2.0 mg = -5.72 Kg (i.e., a imply of 5.72 Kg extra weight misplaced in these taking tirzepatide 15 mg versus these taking semaglutide 2.0 mg)
- Tirzepatide 10 mg versus semaglutide 2.0 mg = -3.52 Kg
- Tirzepatide 5 mg versus semaglutide 1.0 mg = -1.72 Kg
The authors clarify, “In abstract the three tirzepaide doses have been more practical than the three respective semaglutide doses, with the distinction between the 2 medication being bigger with the upper doses.”
As in comparison with placebo, all doses of tirzepatide and semaglutide elevated threat for gastrointestinal adversarial occasions, with tirzepatide 15 mg yielding the best elevated threat (3.6 instances) for nausea, vomiting (4.4 instances) and diarrhea (double the danger).
Between-drug comparisons yielded non-statistically vital outcomes, apart from tirzepatide 15 mg versus semaglutide 1.0 mg (39% elevated vomiting threat) and 0.5 mg (85% elevated vomiting threat), and tirzepatide 15 mg versus semaglutide 0.5 mg (45% elevated threat of nausea). There was no distinction between tirzepatide, semaglutide and placebo concerning threat for severe adversarial occasions.
The authors conclude, “In folks with kind 2 diabetes, tirzepatide 5, 10, and 15 mg have been extra efficacious in decreasing HbA1c in comparison with semaglutide 0.5, 1.0, and a pair of.0 mg, respectively. Tirzepatide additionally was additionally more practical for weight reduction than semaglutide, with a bigger weight-loss impact at larger doses. Excessive-dose tirzepatide (15 mg) was related to elevated threat for vomiting versus low- and medium-dose semaglutide.”
Tirzepatide more practical in blood sugar management and physique weight reduction than semaglutide, reveals meta-analysis (2023, September 22)
retrieved 22 September 2023
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.